Myriad Genetics vs OPKO Health
MYGN and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MYGN and OPK compare
OPKO Health is the larger company, worth 2.3 times as much as Myriad Genetics ($1.2B against $530M).
Myriad Genetics grew revenue faster over the last twelve months (−3.2% versus −11.5% for OPKO Health).
OPKO Health keeps more of each dollar of sales as profit, with a net margin of −12.4% compared with −14.0% at Myriad Genetics.
OPKO Health scores higher on the StockData Score (9 against 8 for Myriad Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MYGN | OPK |
|---|---|---|
| Size and price | ||
| Market cap | $530M | $1.2B |
| Share price | $5.54 | $1.62 |
| Change, 1 year | −17.4% | 26.6% |
| Change, 5 years | −79.2% | −60.8% |
| Beta (5Y) | −0.09 | 0.36 |
| Employees | 2,700 | 2,275 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 | 3 |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× (better) | 2.1× |
| P/B | 1.7× | 1.0× (better) |
| EV/EBITDA | – | 22.0× |
| FCF yield | – | −11.1% |
| Fair value | $18.25 | $1.55 |
| Margin of safety | 69.6% (better) | −4.7% |
| Growth | ||
| Revenue growth (TTM) | −3.2% (better) | −11.5% |
| Revenue growth, 5Y average | −0.63% (better) | −15.8% |
| Profitability | ||
| Gross margin | 68.8% (better) | 40.8% |
| Operating margin | −12.2% | −8.2% (better) |
| Net margin | −14.0% | −12.4% (better) |
| FCF margin | – | −22.8% |
| Return on equity | −32.5% | −5.9% (better) |
| Return on invested capital | −22.8% | −4.0% (better) |
| Financial health | ||
| Debt / equity | 0.40 | 0.00 (better) |
| Net debt / EBITDA | – | −7.19 |
| Interest coverage | −6.0× | – |
| Current ratio | 2.21 | 3.35 (better) |
| Altman Z-score | −0.63 | −0.21 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 3.9% |
| Shareholder yield | 0.00% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 94.1% | 27.2% |
| Held by insiders | 7.2% | 43.6% |
| Insider net buying, 12 months | $655K (better) | −$13.2K |
| Short interest, % of float | 9.5% | 7.8% |
Go deeper
- MYGN stock overview
- MYGN income statement
- MYGN valuation and score
- OPK stock overview
- OPK income statement
- OPK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.